The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
Open accessAbstract
The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Determining the Size and Shape Dependence of Gold Nanoparticle Uptake into Mammalian Cells
Chithrani, B. D., Ghazani, A. A., & Chan, W. C. W. (2006) · Nano Letters · doi:10.1021/nl052396o · Cited by 4,879
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 8×
“Since its discovery, the synthesis method has seen much improvement, allowing a more large scale production and smaller sizes, from 20–50 nm. Liposomal doxorubicin (Doxil®) was the first nanodevice approved by FDA for cancer treatment [79,80], and an additional five formulations have already attained approval—DaunoXom…”
BackgroundInfluentialNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Cited by
A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications
Kerru, N., Gummidi, L., Maddila, S., Gangu, K. K., & Jonnalagadda, S. B. (2020) · Molecules · doi:10.3390/molecules25081909 · Cited by 1,716
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Natural source, bioactivity and synthesis of benzofuran derivatives
Miao, Y.-H., Hu, Y.-H., Yang, J., Liu, T., Sun, J., & Wang, X.-J. (2019) · RSC Advances · doi:10.1039/c9ra04917g · Cited by 354
Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs – a review
Ajani, O. O., Iyaye, K. T., & Ademosun, O. T. (2022) · RSC Advances · doi:10.1039/d2ra02896d · Cited by 305
Bioactive pyrrole-based compounds with target selectivity
Li Petri, G., Spanò, V., Spatola, R., Holl, R., Raimondi, M. V., Barraja, P., & Montalbano, A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112783 · Cited by 261
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Jindal, A., Thadi, A., & Shailubhai, K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.004 · Cited by 257
Metadata
- Authors
- Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-09-16
- Volume
- 20
- Issue
- 9
- Pages
- 16852-16891
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W1709997767
- Cited by
- 716
- References
- 98
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.